Pharmacological treatment of obesity;Tratamiento farmacológico de la obesidad

Anales del Sistema Sanitario de Navarra

Volumn 25, Issue SUPPL. 1, 2002, Pages 143-161

  Salvador, Javier ^a   Silva, C ^a   Santos, E ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Adrenergic Beta antagonists; Cholecystokinin; GLP 1; Obesity; Orlistat; Sibutramine

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLECYSTOKININ; FENFLURAMINE; FLUOXETINE; NEUROPEPTIDE Y; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

APPETITE; CALORIC INTAKE; ENERGY BALANCE; ENZYME INHIBITION; FOOD INTAKE; HUMAN; INGESTION; NORADRENALIN RELEASE; OBESITY; RELIABILITY; REVIEW; RISK BENEFIT ANALYSIS; THERMOGENESIS;

EID: 0036251206     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Overweight and obesity in the United States: Prevalence and trends 1960-1994
2. st century-A vision for all
3. Prevalencia de la obesidad en España
4. Obesity: A time bomb to be defused
5. Research update on serotonin function in bulimia nervosa and anorexia nervosa
6. Serotonin, eating behavior and fat intake
7. Dexfenfluramine-an updated review of its therapeutic use in the management of obesity
8. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double blind placebo-control study
9. Valvular heart disease associated fenfluraminephentermine
10. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability
11. Fluoxetine: A randomized clinical trial in the treatment of obesity
12. Serotoninergic manipulation, meal-induced satiety and eating pattern: Effect of fluoxetine in obese female subjects
13. Neuroscience and appetite behavior research: 25 Years
14. Update on the pharmacotherapy of obesity
15. Use and abuse of appetite-suppressant drugs in the treatment of obesity
16. Long term pharmacotherapy in the management of obesity
17. Appetite suppressant
18. Sibutramine: A review of the pharmacology of a novel anti-obesity agent
19. Sibutramine in weight control: A dose-ranging, efficacy study
20. Sibutramine: A novel agent for obesity treatment
21. Long-term maintenance of weight loss after a very-low-calorie diet: A randomised blinded trial of the efficacy and tolerability of sibutramine
22. Sibutramine-a review of clinical efficacy
23. A double-bblind randomized placebo-controlled trial of sibutramine
24. Long-term weight loss with sibutramine
25. Pharmacology of thermogenic drugs
26. Effect of sibutramine on weight maintenance after weight loss: A randomised trial
27. Sibutramine and fat distribution: Is there a role for pharmacotherapy in abdominal/visceral fat reduction?
28. Weight loss with sibutramine improves glycemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
29. Efficacy and safety of sibutramine in obese white and african american patients with hypertension. A 1 year, double-blind placebo-controlled, multicenter trial
30. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients
31. Últimos avances en el tratamiento farmacológico de la obesidad
32. The dopamine D2 receptor (DRD2) as a major gene in obesity and height
33. Bromocriptine/SKF 38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice
34. Bromocriptine (ergoset) reduces body weight and improves glucose tolerance in obese subjects
35. N-docosahexaenoyl, 3 hydroxytyramine: A dopaminergic compound that penetrates the blood-brain barrier and suppresses appetite
36. Food intake is inversely correlated with central nervous system histamine receptor (H1) concentrations in male Sprague-Dawley rats fed normal, low protein, low energy or poor quality protein diets
37. Effects of intracerebroventricular infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats
38. Hypothalamic neuronal histamine: Implications of its homeostatic control of energy metabolism
39. Mode of acting of orlistat
40. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin
41. Retrospective population-based analysis of dose-response (fetal fat excretion) relationship of orlistat in normal and obese volunteers
42. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor
43. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers
44. The influence of orlistat in the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers
45. Influence of dietary-composition on the inhibition of fat absorption by orlistat
46. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers
47. Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high fat mixed meal in moderately obese subjects
48. Orlistat (RO-18-0647), a lipase inhibitor in the treatment of human obesity; a múltiple dose study
49. The role of orlistat in weight management today
50. Role of orlistat in the treatment of obese patients with type 2 diabetes
51. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlidaemia
52. Relationship between improved postprandial lipemia and low density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor
53. A one year trial to assess the value of orlistat in the management of obesity
54. Relapse reducing effects of acarbose after weight reduction in severely obese subjects
55. Relationship between food intake and metabolic rate in rats treated with β-adrenergic agonist
56. Beta-3 adrenergic agonist (BRL-37344) decreases food intake
57. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with5-hydroxytryptophan
58. Effects of two weeks fat replacement by olestra on food intake and energy metabolism
59. Metabolic effects of fat substitution with olestra
60. Effects of olestra, a noncaloric fat substitute, on daily energy and fat intakes in lean men
61. Fat susbstitution and food intake: Effect of replacing fat with sucrose polyester at lunch or evening meals
62. st century
63. Epinephrine produces a prolonged elevation in metabolic rate in humans
64. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial
65. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women
66. Use of drugs in the treatment of obesity
67. Challenges in obesity management
68. Prospects for β-3-adrenoreceptors agonists in the treatment of obesity and diabetes
69. Beta-agonists as antiobesity, antidiabetic and nutrient partitioning agents
70. Genetic variation in the β-3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity
71. A pathogenic role of visceral fat β-3 adrenoceptors in obesity
72. Clinical studies with the β-adrenoceptor agonist BRL 26830 A
73. Obesity and diabetes and the β-3 adrenergic receptor
74. Mice expressing human but not murine β-3 adrenergic receptors under the control of human gene regulatory elements
75. Beta-adrenoceptor subtypes mediating the metabolic effects of BRL 35135 in man
76. Effects of BRL 35135, a β adrenoreceptor agonist with novel selectivity on glucose tolerance and insulin sensivity in obese subjects
77. BRL 35135, a potent and selective atypical β-adrenoreceptor agonist
78. Increase in insulin action and fat oxidation after treatment with CL 316243, a highly selective β-adrenoreceptor agonist in humans
79. Aplicación terapéutica de los agonistas adrenérgicos β-3 en la obesidad y la diabetes
80. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure
81. Treatment of obese, diet restricted subjects with growth hormone for 11 weeks. Effects on anabolism, lipolysis and body composition
82. Energy expenditure and body composition in growth hormone deficient adults on exogenous growth hormone
83. Ineffectiveness of human chorionic gonadotropin in weight reduction: A double-blind study
84. Human chorionic gonadotropin (hCG) treatment of obesity
85. Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans
86. Androgen treatment of abdominally obese men
87. Testosterone and regional fat distribution
88. Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men
89. Body-composition, energy-utilization and nitrogen-metabolism with a severely restricted diet supplemented with dihydroxyacetone and pyruvate
90. Inhibition of lipid deposition and weight gain with the addition of dihydroxyacetone and pyruvate to the diet after hypocaloric dietary therapy for obesity
91. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent
92. Effects of recombinant leptin therapy in a child with congenital leptin deficiency
93. Recombinant leptin for weight loss in obese and lean adults. A randomized, controlled, dose-escalation trial
94. Weekly subcutaneous pegylated recombinant native human leptine (PEG-OB) administration in obese men
95. Editorial: Leptin as a therapeutic agent. Trials and tribulations
96. Chronobiology of recombinant leptin therapy
97. Topiramate: A review of pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy
98. Treatment of affective disorder and obesity with topiramate
99. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats
100. Treatment of binge-eating disorder with topiramate: A clinical case series
101. Enteroglucagon
102. Hamster preproglucagon contains the sequence of glucagon and two related peptides
103. Control of food intake
104. A role for glucagon-like peptide-1 in the central regulation of feeding
105. Attenuated GLP-1 secretion in obesity: Cause or consequence
106. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men
107. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
108. Glucagon-like peptide 1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
109. Energy intake and appetite are suppressed by glucagon-like peptide 1 (GLP-1) in obese men
110. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats
111. Exendin-4 decelerates food intake, weight gain and fat deposition in Zucker rats
112. Behavioral effects of corticotropin-releasing factor: Localization and characterization of central effects
113. Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal
114. Neurochemical-neuroendocrine systems in the brain controlling macronutrient intake and metabolism
115. Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats
116. Oleoyl-estrone treatment affects the ponderostat setting differently in lean and obese Zucker rats
117. Increased food intake after type A but not type B cholecistokinin receptor blockade
118. Hypothalamic and genetic obesity in experimental animals: An autonomic and endocrine hypothesis
119. Cholecystokinin decreases food intake in rats
120. Satiating effect of cholecystokinin
121. Biological actions of cholecystokinin
122. Effects of cholecystokinin on sympathetic activity to interscapular brown adipose tissue
123. Potent and sustained satiety actions of a cholecystokinin octapeptide analogue
124. 3-(1H-indazol-3-ylmethyl)-1, 5-benzodiazepines: CCK-A agonists that demonstrate oral activity as satiety agents
125. Novel molecular targets for the treatment of obesity
126. A role for melanin-concentrating hormone in the central regulation of feeding behavior
127. Galanin in the hypothalamus of fed and fasted lean and obese Zucker rats
128. Naloxone decreases food intake in obese humans
129. Current and potential drugs for treatment of obesity
130. New approaches in the pharmacological treatment of obesity